No Data
beijing beilu pharmaceutical (300016.SZ) obtained GMP certification from the Brazilian National Health Surveillance Agency.
Beijing Beilu Pharmaceutical (300016.SZ) announced that recently, the company has obtained approval from the Brazilian National Health Surveillance Agency ("ANVISA")...
Hokuriku Pharmaceutical: Third quarter report 2024
Beijing Beilu Pharmaceutical (300016.SZ): Gadoxetic Acid Glucosamine Injection passed the consistency evaluation.
On October 21st, Beijing Beilu Pharmaceutical (300016.SZ) announced that the company recently received the approval and issuance of specifications of gadolinium diethylenetriaminepentaacetic acid glucosamine injection: 10ml: 4.69g, 12ml: 5.63g, in the 'Supplementary Application Approval Notice for Pharmaceutical Products' (Notice Numbers: 2024B04775, 2024B04774). Gadolinium diethylenetriaminepentaacetic acid glucosamine injection (10ml: 4.69g, 12ml: 5.63g) has passed the evaluation of generic drug quality and efficacy consistency. Gadolinium diethylenetriaminepentaacetic acid glucosamine injection is a commonly used paramagnetic contrast agent in domestic clinical practice.
Beijing Beilu Pharmaceutical (300016.SZ): Haichang Pharmaceutical passed the pharmaceutical GMP compliance inspection.
Beijing Beilu Pharmaceutical (300016.SZ) announced that the company's holding subsidiary Zhejiang Haichang Pharmaceutical Co., Ltd. (referred to as "...
Beijing Beilu Pharmaceutical (300016.SZ): Currently has a production line for iodine contrast agents with an annual output of 1000 tons, totaling 7 varieties.
Beijing Beilu Pharmaceutical (300016.SZ) received specific inquiries on September 11, 2024 regarding the 'company's capacity utilization'. The company stated that the current capacity utilization of Beijing Beilu Pharmaceutical can meet the business development needs for the next two to three years. In order to meet the continuous growth demands of future business, the company is actively expanding its capacity. As an important subsidiary of the company, Haichang Pharmaceutical has added 50 tons of iodinated sea alcohol API production capacity in 2023 and increased the production line for 100 tons of iodinated mepivacaine API, which currently includes a total of 7 varieties of production lines for annual production of 1,000 tons of iodinated contrast agent projects.
Beijing Beilu Pharmaceutical (300016.SZ): In the first half of the year, all of the company's comparative agents successfully entered the international market and achieved significant revenue growth.
On September 11, 2024, Beijing Beilu Pharmaceutical (300016.SZ) received a specific object investigation regarding the "company's expansion in the overseas market". The company stated that after years of solid preparation and unremitting exploration, the effectiveness of the company's overseas market expansion work has been highlighted. In the first half of 2024, the company's contrast agent product line successfully entered the overseas market and achieved a significant increase in revenue. In terms of active pharmaceutical ingredients, not only did the iodine-based active pharmaceutical ingredients of Haichang Pharmaceutical continue to expand in the overseas market, but also the gadolinium-based active pharmaceutical ingredients produced by the Cangzhou branch gradually achieved internationalization. With the EDQM GMP certification in the European Union and the compliance certification in Brazil.
No Data
